Two serious health conditions, obesity and atopic dermatitis (AD), share some pathological
features such as insulin resistance, leptin resistance and inflammation, and a growing body …

Background Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds
to interleukin (IL)-13. Objectives To evaluate the efficacy and safety of lebrikizumab …

Background The incidence of adult‐onset atopic dermatitis (AOAD) is increasing. However,
the unique characteristics of AOAD compared to pediatric‐onset AD persisting into …

Atopic dermatitis (AD) is a chronic pruritic skin disease with a complex pathogenesis
underlying its heterogeneous clinical phenotypes and endotypes. The skin manifestation of …

Atopic dermatitis (AD) and chronic urticaria (CU) are common skin diseases with an
increasing prevalence and pathogenesis that are not fully understood. Emerging evidence …

Importance Older adults with atopic dermatitis (AD) face unique treatment challenges,
including comorbidities, polypharmacy, and a higher risk for infections (eg, herpes zoster) …

Background: Cross-sectional evidence has suggested a high prevalence of atopic diseases
in patients with hidradenitis suppurativa (HS). However, there is a lack of evidence based on …

Background Adults aged≥ 60 years are often underrepresented in atopic dermatitis (AD)
clinical trials; age-related comorbidities may impact treatment efficacy and safety. Objective …

Atopic dermatitis, the most common chronic inflammatory skin disease, can occur at any
age, and patterns of disease activity vary over time. Both prevalence and incidence are …

The burden of atopic dermatitis (AD) appears to be increasing in adult and elderly patients.
The aim of this study was to analyse the nationwide database of the Finnish Institute for …